PepLabo Download

Foundayo™ and frequent urination

Needing the bathroom more often after starting a new medicine is the kind of change people tend to notice but rarely mention. With Foundayo™, the question has a fairly clear answer in the documents: frequent urination is not a listed effect, and it was uncommon in the orforglipron trials. That still leaves the familiar causes, from drinking more and caffeine to a urinary infection, high blood sugar, other medicines and sleep apnea. This page sets out what the label and trial registries show, those everyday causes, and why the change the label actually warns about runs the other way.

Published · Updated · Foundayo™: side effects by symptom · Written by the PepLabo editorial team

What Foundayo™ documents say about urine

Foundayo™ is a daily orforglipron tablet approved in the US for weight management [1]. Neither its Prescribing Information nor its Medication Guide lists frequent or urgent urination [1][2]. The entries that do touch the urinary tract are about fluid loss: acute kidney injury was reported in 0.2% of treated adults against 0.05% on placebo, mostly after stomach side effects caused dehydration [1].

Orforglipron is broken down in the liver and its products pass into the gut, so very little reaches the urine [1]. No European or Canadian product information is available for comparison: the EMA’s committee gave a positive opinion in October 2026 with no EMA product information yet, and Health Canada lists no Foundayo™ product [3][4].

Urination in Foundayo™ documents, checked 20 October 2026
SourceFrequent urinationRelated entry
US Prescribing Information [1]Not listedAcute kidney injury 0.2% vs 0.05% on placebo; less than 1% of a dose in urine
US Medication Guide [2]Not listedDrink fluids to lower the chance of dehydration
European Medicines Agency [3]No product information yetPositive opinion of 15 October 2026
Health Canada [4]No entry foundNo product monograph

Urinary entries in the trial registries

The two weight trials behind the label, ATTAIN-1 and ATTAIN-2, posted non-serious events only when they reached 5% of a group [5][6]. Three diabetes trials posted every event [7][8][9]. Their trial doses of 3, 12 and 36 mg are not Foundayo™ tablet strengths, and treating type 2 diabetes is outside the US indication [1].

Urination and urinary infection entries (people affected out of people treated)
Trial [source]EntryComparison groupOrforglipron, low to high dose
ATTAIN-2, obesity with type 2 diabetes [6]Urinary tract infectionPlacebo 24/628 (3.8%)13/328 (4.0%); 18/331 (5.4%); 16/321 (5.0%)
ATTAIN-1, obesity without diabetes [5]Urinary tract infection, seriousPlacebo 1/9481/723; 0/724; 1/728 (non-serious cases under 5% in every group)
ACHIEVE-1, double blind [7]Frequent urinationPlacebo 0/1382/143; 0/137; 0/141
ACHIEVE-5, double blind, with insulin [9]Frequent urination; urinary tract infectionPlacebo 1/140; 6/140None; 2/137, 3/132, 4/135
ACHIEVE-2, open label [8]Passing large amounts of urine; urinary tract infectionDapagliflozin 1/240; 12/2400, 1 and 0 of about 240; 8/240, 3/241, 5/241

Reading the urinary numbers

  • Frequent urination was reported by at most two people in a group of 130 to 240, and a placebo group had a case too [7][9].
  • In ATTAIN-2, urinary tract infections were a little more common on the two higher doses than on placebo; the registry gives no test of whether that gap is more than chance [6].
  • In ACHIEVE-5 the pattern ran the other way, with the most infections on placebo [9].
  • Dapagliflozin, an SGLT-2 inhibitor, had the most infections in ACHIEVE-2. That trial was open label, so people knew which medicine they were taking [8].

Why you might still be going more often

Drinking more: the Foundayo™ Medication Guide asks you to drink fluids to lower the chance of dehydration [2], and more fluid in means more urine out. That is the intended effect, not a side effect.

Blood sugar: MedlinePlus lists urinating often among the signs of high blood sugar [13]. In Trial 2, adults with type 2 diabetes saw HbA1c fall by 1.2 to 1.7 percentage points on Foundayo™ against 0.4 on placebo [1], so in diabetes frequent urination is more a reason to check glucose than a sign of the tablet.

Other medicines: in a Medicare cohort, SGLT-2 inhibitors were linked to higher 24-hour urine volume, while GLP-1 medicines showed no change [10]. MedlinePlus also names diuretics (water pills) [11]. Half of the people in the label’s trials had high blood pressure, and Trial 2 allowed oral diabetes medicines other than DPP-4 inhibitors [1].

Sleep apnea: NHLBI lists waking often at night to urinate among its symptoms [15], and 11% of the label’s trial population had obstructive sleep apnea [1]. Foundayo™ is not approved in the US to treat sleep apnea [1].

Other everyday causes

MedlinePlus lists common and less common reasons for needing to urinate often or urgently [11]:

  • A urinary tract infection, or swelling and infection of the urethra.
  • An enlarged prostate in middle-aged and older men; vaginitis in women.
  • Caffeine and alcohol.
  • Anxiety, nerve-related problems, spine problems or a stroke.
  • Pregnancy, overactive bladder, interstitial cystitis or, rarely, a bladder tumour.

The change that matters more: less urine

The Foundayo™ label is concerned with too little fluid, not too much urine. Nausea, vomiting and diarrhoea were common in the trials, especially while the dose was being raised, and the label links them to the reported cases of kidney injury [1]. MedlinePlus lists not urinating much, or very dark yellow urine, among the signs of dehydration, along with thirst, a dry mouth and dizziness [14].

So a drop in urine during a bout of vomiting or diarrhoea is the urinary change that needs a call. The Medication Guide asks you to tell your provider right away if nausea, vomiting or diarrhoea does not go away [2].

What general guidance suggests

MedlinePlus suggests writing down when you urinate and roughly how much, a record called a voiding diary, and bringing it to your appointment [11]. For night-time urination it suggests not drinking a lot before bed and cutting down on drinks that contain alcohol or caffeine [11].

Cutting fluids during the day to avoid bathroom trips is not part of that advice, and it works against the Medication Guide’s request to drink enough on Foundayo™ [2][11]. If urination stays frequent, the cause is something to work out with your provider, who may test your urine or blood sugar [11][13].

Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.

When to get help

SignWho to contactHow fastSource
Urinary symptoms with fever, back or side pain, vomiting or shaking chillsYour provider, right awayTodayMedlinePlus [11]
Very little or very dark urine with thirst or dizziness after vomiting or diarrhoeaYour prescriber, right awayTodayMedlinePlus [14]; Foundayo™ Medication Guide [2]
Frequent urination with more thirst or appetite, tiredness or sudden weight lossYour provider, right away; check blood sugar if you have diabetesTodayMedlinePlus [11][13]
Burning when you urinate, or cloudy or reddish urineYour doctor for a urine testTodayMedlinePlus [12]
Frequent or urgent urination without drinking much more, or leaks that change your routineYour doctorAt your next appointmentMedlinePlus [11]
Waking at night to urinate together with loud snoring or daytime sleepinessYour doctor; a sleep study may be neededAt your next appointmentNHLBI [15]

Questions

Does Foundayo™ make you pee more?

It is not a listed side effect [1]. In trials that recorded every event, frequent urination affected at most two people per group, and placebo had a case as well [7][9].

Does Foundayo™ cause urinary tract infections?

They are not listed in the label [1]. In ATTAIN-2 they were slightly more frequent on higher doses than placebo, while in ACHIEVE-5 placebo had the most; the data do not show a clear effect [6][9].

Should I drink less to avoid bathroom trips?

The Medication Guide asks you to drink fluids to lower the chance of dehydration [2]. MedlinePlus suggests limiting drinks before bed and cutting back on caffeine and alcohol rather than drinking less overall [11].

I take an SGLT-2 inhibitor too. Which one makes me urinate?

In a Medicare study, SGLT-2 inhibitors were linked to higher urine volume and GLP-1 medicines were not [10]. Ask your prescriber before changing either medicine.

Could frequent urination mean my blood sugar is high?

It can. MedlinePlus lists frequent urination and thirst among signs of high blood sugar [13]. Foundayo™ lowered HbA1c in adults with type 2 diabetes in Trial 2 [1].

I wake up at night to urinate. Could it be sleep apnea?

It is one of the symptoms NHLBI lists, along with loud snoring and daytime sleepiness [15]. A doctor can decide whether a sleep study is needed.

Sources

Sources checked on

  1. FOUNDAYO™ (orforglipron) tablets Prescribing Information, Eli Lilly and Company Revised 07/2026. Sections 1, 5.4, 6.1 (trial population, acute kidney injury, gastrointestinal adverse reactions), 12.3 and 14 (Trial 2, Table 7). No entry for frequent urination.
  2. FOUNDAYO™ (orforglipron) Medication Guide, Eli Lilly and Company Issued 07/2026.
  3. Foundayo: opinion and summary of positive opinion (EMA/CHMP/229918/2026), European Medicines Agency Opinion adopted 15/10/2026; no EMA product information available yet.
  4. Drug Product Database, Health Canada Searched for Foundayo and orforglipron on 20 October 2026: no entry.
  5. A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1), results, ClinicalTrials.gov NCT05869903. Serious adverse events listed in full; other adverse events at a 5% threshold.
  6. A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2), results, ClinicalTrials.gov NCT05872620. Serious adverse events listed in full; other adverse events at a 5% threshold.
  7. A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (ACHIEVE-1), results, ClinicalTrials.gov NCT05971940. All adverse events listed.
  8. A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2), results, ClinicalTrials.gov NCT06192108. Open label; all adverse events listed.
  9. A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5), results, ClinicalTrials.gov NCT06109311. All adverse events listed.
  10. Schaub JA et al. The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on 24-hour urine parameters: a retrospective cohort study. Kidney360 2025 Retrospective Medicare cohort; PubMed abstract.
  11. Frequent or urgent urination, MedlinePlus Medical Encyclopedia (U.S. National Library of Medicine)
  12. Urinary Tract Infections, MedlinePlus (U.S. National Library of Medicine)
  13. Hyperglycemia, MedlinePlus (U.S. National Library of Medicine)
  14. Dehydration, MedlinePlus Medical Encyclopedia (U.S. National Library of Medicine)
  15. Sleep Apnea: Symptoms, National Heart, Lung, and Blood Institute (NIH)

Set up your lab tonight.

It takes a few minutes. Pep will be waiting.